The World’s First Autonomous Blood Drawing Device

Informations projet

VD-1

N° de convention de subvention: 190176843

DOI

10.3030/190176843

Projet clôturé

Date de signature de la CE 14 Juillet 2023

Date de début 1 Juin 2023

Date de fin 28 Février 2025

Financé au titre de

• The European Innovation Council (EIC)

Coût total

€ 2 975 301,25

Contribution de l’UE

€ 2 082 710,88

Coordonné par

VITESTRO BV
Netherlands

Periodic Reporting for period 2 - VD-1 (The World’s First Autonomous Blood Drawing Device)

Période du rapport: 2024-04-01 au 2025-02-28

Résumé du contexte et des objectifs généraux du projet

Vitestro has created the first fully-autonomous device that draws blood from patients. Our solution, called VD-1, performs the whole
venipuncture procedure, from vein detection to bandage application, without any human intervention. We have fully developed our
technology in-house and protected it with seven patents. More than 2,500 patients have tried our solution: the user acceptance, first-time
success rate, and hemolysis rate are comparable to those measured using human nurses. The VD-1 will mitigate the chronic shortage
of healthcare personnel. It will also standardize the venipuncture process, which has been substantially unchanged for decades. We target
two categories of customers – lab chains and hospital labs – and we have launching customers in both of them. Vitestro has a team of
over 70 people, including technical, medical, regulatory, and commercial expertise.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

- We worked on the A.D.O.P.T. Trial, which is the largest trial in autonomous blood drawing worldwide.
- We enrolled the first 1,400 patients in 4 European Hospital Laboratory sites.
- We have completed the technology objectives, increase safety and performance and preparing the device for industrialization.
- We have solved multiple technical challenges in integration of hardware and software.
- We have obtained CE marking and can thereby sell the device within the EU.
- We have placed the first two devices in a commercial setting in the OLVG hospital in Amsterdam

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

- We have raised a Series A-1 funding round of €20M with a consortium of multiple EU and U.S. partners, including EIC Fund
- We have presented trial results at Dutch congress NVKC as well as NVML
- We have signed contracts with 5 different customers for a total of 13 devices
- We have grown the team from 50 to ~100 people
- We have participated as a semi-finalist in the ADLM Disruptive Innovation Award
- We have a total of nine patents filed on all essential parts of the device